TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituxima…
Biotechnology
US, New York [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -20.31 | -238.97 | -198.64 | |
| Graham Fair Price | -15.76 | 1.34 | 1.59 | |
| PEG | 399.40 | 1.88 | 0.38 | |
| Price/Book | -11.42 | 13.49 | 15.23 | |
| Price/Cash Flow | -42.22 | -263.13 | -185.01 | |
| Prices/Earnings | -18.97 | -50.42 | -42.38 | |
| Price/Sales | -38.79 | 34.02 | 55.58 | |
| Price/FCF | -42.22 | -263.13 | -185.01 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 11.44 | 0.91 | 0.82 | |
| Operating Margin | 48.56 | -0.15 | -0.28 | |
| ROA | 34.43 | -0.03 | -0.04 | |
| ROE | -0.09 | -0.07 | 25.55 | |
| ROIC | -0.05 | -0.04 | 27.77 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 9.07 | -99.91 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -1.11 | 0.26 | -76.78 | |
| EPS QOQ | -1.13 | 0.27 | -76.18 | |
| FCF QOQ | -1.16 | 0.38 | -67.29 | |
| Revenue QOQ | -0.73 | 0.44 | -39.64 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 451.05 | 1266.47 | 180.78 | |
| Days Sales Outstanding (DSO) | 104.58 | 92.14 | -11.89 | |
| Inventory Turnover | 0.20 | 0.07 | -64.38 | |
| Debt/Capitalization | 0.39 | 0.39 | 0.84 | |
| Quick Ratio | 5.00 | 2.76 | -44.87 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 1.12 | 1.10 | -2.37 | |
| Cash | 1.52 | 1.43 | -5.61 | |
| Capex | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | -0.09 | -0.06 | 39.20 | |
| Revenue | 0.31 | 0.43 | 41.28 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad